Helicobacter pylori Screening Study

INTERVENTION: Participants seen in treatment weeks, if H. pylori positive, were offered a one week course of eradication therapy comprising twice‐daily oral metronidazole 400 mg, clarithromycin 250 mg and lansoprazole 30 mg. No screening or treatment was offered to control participants. Follow‐up is for all participants, for 15 years or more after recruitment, with notifications of all cancers and of deaths by cause from the Information Centre for Health and Social Care and the General Register Office for Scotland. CONDITION: Prevention of stomach cancer ; Cancer ; Gastric cancer PRIMARY OUTCOME: Incidence of and death from stomach cancer SECONDARY OUTCOME: 1. Incidence of and death from oesophageal cancer ; 2. Death from ischaemic heart disease; 3. Death from gastric bleed or peptic ulcer INCLUSION CRITERIA: 1. Healthy NHS registered UK residents 2. Male participants aged 35‐69 3. Female participants aged 45‐69 4. Patients attending a Bupa Wellness Centre for a health screen